Tirzepatide vs Survodutide
GLP-1/GIP Dual Agonist · GLP-1/Glucagon Dual Agonist
Here is how these two compounds compare, based on published research, not marketing claims.
Tirzepatide
FDA-approved dual GIP and GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) with the largest mean body weight reduction among approved GLP-1 medications.
Survodutide
An investigational GLP-1 plus glucagon dual agonist with Phase II liver fat data leading the obesity peptide class; not yet FDA-approved.
Tirzepatide
1849 studies
47 human trials
FDA-Approved
Survodutide
87 studies
8 human trials
Not FDA-Approved
What it does
Tirzepatide
Activates two appetite-control receptors at once: GLP-1 and GIP. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound).
Survodutide
An investigational dual-receptor agonist studied for weight management and metabolic liver disease. Activates two receptors at once: GLP-1 (the appetite-control receptor semaglutide uses) and glucagon (a separate receptor that increases energy expenditure and helps the liver oxidize stored fat). Phase II trials showed up to 19% mean body weight reduction at 46 weeks. Currently in Phase III development; not yet FDA-approved.
How it works
Tirzepatide
Engineered to bind two natural appetite hormones' receptors at once. The GLP-1 receptor tells the brain the body is full and slows stomach emptying (the same pathway as semaglutide). The GIP receptor adds enhanced fat oxidation and improved lipid metabolism. The dual signal does what GLP-1 alone does, plus the GIP component, which appears to drive the larger weight-loss effect. Like semaglutide, it stays active in the body for about a week, allowing once-weekly dosing.
Survodutide
An engineered peptide that binds two receptor systems at once. The GLP-1 side reduces appetite and slows gastric emptying (the same mechanism semaglutide uses). The glucagon side adds increased energy expenditure (more calories burned at rest) and increased hepatic fat oxidation (the liver burning stored fat for fuel). The glucagon mechanism is what differentiates survodutide from GLP-1-only medications and drives the strong liver fat reduction seen in published trials.
How often
Tirzepatide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen. The SURPASS trial protocols (type 2 diabetes) and SURMOUNT trial protocols (chronic weight management) used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Survodutide
Trial protocols use once-weekly subcutaneous injection. The Phase II obesity trial (Le Roux et al. 2024, Lancet) tested four ascending doses over 46 weeks. The SYNCHRONIZE Phase III obesity program is currently underway, alongside parallel Phase III trials for MASH (metabolic dysfunction-associated steatohepatitis) and type 2 diabetes. Survodutide is not yet FDA-approved; clinical availability is restricted to investigational protocols.
How strong
Tirzepatide
The largest weight-loss effect of any FDA-approved peptide to date. In the SURMOUNT-1 trial, average weight loss reached 22.5% at the highest dose over 72 weeks. The effect builds as the dose titrates up.
Survodutide
Phase II reported up to 19% mean body weight reduction at the highest dose over 46 weeks (Le Roux et al. 2024, Lancet). The same trial reported 47% relative liver fat reduction at the highest dose, the strongest liver fat data among current Phase II/III obesity peptides. Phase III readouts from the SYNCHRONIZE program are expected through 2027.
Main tradeoff
Tirzepatide
Larger average weight loss than semaglutide in head-to-head trials (SURPASS-2). Cardiovascular outcomes data is still maturing: semaglutide has SELECT, tirzepatide's parallel trial (SURPASS-CVOT) is ongoing. Less long-term safety data overall because tirzepatide is the newer of the two compounds. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Survodutide
Phase II data shows survodutide weight-loss effects similar to semaglutide and slightly below tirzepatide; the differentiator is the glucagon component's impact on liver fat. The structural difference is regulatory status: semaglutide and tirzepatide are FDA-approved; survodutide is in Phase III development. Less long-term safety data overall because the compound is investigational. The glucagon receptor's contribution to glucose homeostasis differs from pure GLP-1 agonism; whether this affects glycemic control over multi-year use is empirically open.
Best for
Tirzepatide
- Adults with overweight or obesity seeking the largest average weight reduction available in trials
- Adults with type 2 diabetes seeking superior HbA1c reduction (SURPASS-2 head-to-head data)
- Clinical contexts willing to use a newer compound with less long-term safety data than semaglutide
Survodutide
- Research interest in dual-receptor (GLP-1 + glucagon) mechanism
- Particular interest in metabolic dysfunction-associated steatohepatitis (MASH) where the glucagon pathway shows strong Phase II liver fat data
- Patients in SYNCHRONIZE or other survodutide clinical trials under investigator supervision
How to choose
A good fit for Tirzepatide
- Need an FDA-approved option clinically available today
- Largest mean body weight reduction in a currently approved GLP-1 medication
- Established post-marketing safety data and pharmacovigilance through Eli Lilly
- Insurance coverage and physician prescribing pathways exist for the FDA-approved indications
A good fit for Survodutide
- Research interest in metabolic dysfunction-associated steatohepatitis (MASH) where the glucagon pathway shows leading Phase II liver fat data
- Particular interest in dual GLP-1 plus glucagon mechanism over GIP
- Comfortable waiting through Phase III SYNCHRONIZE readouts (2027 timeframe)
- Enrolled in survodutide clinical trials under investigator supervision
Consider both across time
Tirzepatide and survodutide are both dual-receptor agonists, but they pair GLP-1 with different second receptors. Tirzepatide adds GIP for enhanced fat metabolism; survodutide adds glucagon for increased energy expenditure and direct hepatic fat oxidation. Tirzepatide is FDA-approved and clinically available; survodutide remains in Phase III development. The two compounds target overlapping but distinct metabolic outcomes: tirzepatide leads in approved weight management; survodutide leads in Phase II liver fat reduction. For broader context including the FDA-approved single-receptor option, see Semaglutide vs Tirzepatide.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
- Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- Glucagon Receptor
- GLP-1 Receptor activates Dual GLP-1 + Glucagon Signaling; Glucagon Receptor activates Dual GLP-1 + Glucagon Signaling
- Dual GLP-1 + Glucagon Signaling connects to Appetite + Energy Expenditure
- Dual GLP-1 + Glucagon Signaling connects to Hepatic Fat Oxidation
- Appetite + Energy Expenditure connects to Weight + Liver Outcomes; Hepatic Fat Oxidation connects to Weight + Liver Outcomes
Tirzepatide activates two receptors at once: GLP-1 (appetite suppression, gastric emptying) and GIP (enhanced fat metabolism).
Survodutide activates both GLP-1 and glucagon receptors at once. The GLP-1 side mirrors tirzepatide; the glucagon side adds increased energy expenditure and direct liver fat oxidation.
Research Evidence
Tirzepatide sits at PSI's highest evidence tier (FDA Approved), with the SURPASS program establishing type 2 diabetes efficacy and the SURMOUNT program establishing chronic weight management efficacy. Survodutide sits at PSI's Human Trials tier: the Le Roux et al. 2024 Lancet Phase II trial reported 19 percent mean body weight reduction at 46 weeks plus 47 percent relative liver fat reduction at the highest dose, the strongest liver fat data among current obesity peptides. The SYNCHRONIZE Phase III obesity program is currently underway alongside parallel Phase III trials for MASH and type 2 diabetes. For research where regulatory approval matters, tirzepatide is the only option. For research focused specifically on the GLP-1 plus glucagon dual mechanism and metabolic liver disease, survodutide leads.
- 1.
For available, proven weight management, tirzepatide is approved and effective.
- 2.
For liver fat reduction specifically, survodutide's glucagon mechanism may offer unique advantages.
- 3.
For clinical decision-making today, tirzepatide is the evidence-based option.
- 4.
For the future of metabolic medicine, both dual-agonist approaches are shaping the field.
Key Limitations
- •Survodutide is not yet approved.
- •No head-to-head trial exists.
- •Different patient populations in Phase 2 trials limit comparison.
- •The optimal second target (GIP vs glucagon) is an active area of scientific debate.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Tirzepatide
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Safety Comparison
Tirzepatide carries the FDA boxed warning for thyroid C-cell tumors based on rodent studies and the GLP-1 class side effect profile (nausea, vomiting, diarrhea, usually transient and dose-dependent). Long-term post-marketing data has accumulated since 2022 FDA approval. Survodutide has Phase II safety data showing GI side effects similar to the GLP-1 class but no long-term post-marketing data exists yet. The glucagon receptor's contribution introduces an open question about glucose homeostasis over multi-year use that tirzepatide does not have. Whether the class-shared bone-loss-with-weight-loss signal observed in semaglutide and tirzepatide users (Liu et al. 2026, J Clin Endocrinol Metab) extends to dual agonists like survodutide is empirically open.
Tirzepatide
Well-characterized from SURPASS and SURMOUNT trials. GI side effects common. Growing post-marketing data.
Survodutide
Phase 2 data available. Phase 3 ongoing. Long-term safety not yet established.
What the Research Suggests
Tirzepatide is proven. Survodutide is promising. The choice between GIP and glucagon as GLP-1's partner is one of the most interesting questions in metabolic medicine right now.